Medical oncologist Dr Philipp Ivanyi joined us at ESMO 2023 to share his thoughts on the latest precision oncology data to emerge from the congress and the possible impact on clinical practice.
Cancer of unknown primary
- CUPISCO: In patients with newly diagnosed, unfavourable, non-squamous CUP that responded to induction CTX, CGP with MGT improved PFS, thereby supporting a precision oncology approach in these patients
- CUP-ONE: CTID molecular-expression classifier demonstrated similar performance overall to specialist C-IHC
- Fudan CUP-001: Site-specific treatment guided by the approved 90-gene expression assay resulted in more therapy options, and significantly improved PFS with favourable OS vs empirical chemotherapy in patients with de novo CUP
- ARCAGEN: Molecular profiling of rare cancers identified many targetable alterations, and should be more routinely performed
- DESTINY-PanTumor01 (DPT-01): In heavily pretreated patients with limited treatment options, T-DXd demonstrated encouraging anticancer activity and long DoR across multiple tumour types with HER2m and a range of HER2 expression levels
- LIBRETTO-531: First-line selpercatinib prolonged PFS, improved ORR, and achieved a better OS vs MKIs, and should now be considered the preferred first-line standard of care for patients with advanced RET-mutant MTC